Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Raëf Abdallah"'
Autor:
Julien Taieb, Raëf Abdallah
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 2 (2019)
Externí odkaz:
https://doaj.org/article/f67687f94a4e440a87a90e0b96c35465
Autor:
Dilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F. Palm, Giuseppe Malleo, Ryan K. Schmocker, Raëf Abdallah, Changhoon Yoo, Walid L. Shaib, Marcel André Schneider, Elena Rangelova, Yoo Jin Choi, Hongbeom Kim, J. Bart Rose, Sameer Patel, Gregory C. Wilson, Sarah Maloney, Lea Timmermann, Klaus Sahora, Fabian Rössler, Víctor Lopez-Lopez, Emanuel Boyer, Laura Maggino, Thomas Malinka, Jeong Youp Park, Matthew H. G. Katz, Laura Prakash, Syed A. Ahmad, Scott Helton, Jin-Young Jang, Sarah E. Hoffe, Roberto Salvia, Julien Taieb, Jin He, Pierre-Alain Clavien, Ulrike Held, Kuno Lehmann
Publikováno v:
Annals of Surgical Oncology.
Autor:
Dilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F. Palm, Giuseppe Malleo, Ryan K. Schmocker, Raëf Abdallah, Changhoon Yoo, Walid L. Shaib, Marcel André Schneider, Elena Rangelova, Yoo Jin Choi, Hongbeom Kim, J. Bart Rose, Sameer Patel, Gregory C. Wilson, Sarah Maloney, Lea Timmermann, Klaus Sahora, Fabian Rössler, Víctor Lopez-Lopez, Emanuel Boyer, Laura Maggino, Thomas Malinka, Jeong Youp Park, Matthew H. G. Katz, Laura Prakash, Syed A. Ahmad, Scott Helton, Jin-Young Jang, Sarah E. Hoffe, Roberto Salvia, Julien Taieb, Jin He, Pierre-Alain Clavien, Ulrike Held, Kuno Lehmann
Publikováno v:
Annals of Surgical Oncology.
Background Pancreatic cancer often presents as locally advanced (LAPC) or borderline resectable (BRPC). Neoadjuvant systemic therapy is recommended as initial treatment. It is currently unclear what chemotherapy should be preferred for patients with
Autor:
Kayvan, Mohkam, Raëf, Abdallah, Gisèle, N'kontchou, Nathalie, Ganne, Louise, Barbier, Ephrem, Salamé, Petru, Bucur, Michel, Rayar, Fabien, Robin, Karim, Boudjema, Daniel, Pietrasz, Daniel, Cherqui, René, Adam, Chetana, Lim, Eric, Savier, Olivier, Scatton, Charlotte, Maulat, Bertrand, Suc, Fabrice, Muscari, Alexis, Laurent, Christophe, Duvoux, Bruno, Heyd, Célia, Turco, Alexandre, Doussot, Philippe, Merle, Teresa, Antonini, Mickaël, Lesurtel, Cyril, Cossé, François, Durand, Olivier, Soubrane, François, Cauchy, Jean-Yves, Mabrut
Publikováno v:
Transplantation. 106:1411-1420
The ABO blood group system may influence tumorigenesis, but its prognostic value in liver transplantation (LT) for hepatocellular carcinoma (HCC) has never been assessed.All consecutive patients who underwent LT for HCC between 2013 and 2017 at 9 cen
Autor:
Raëf Abdallah, Shulin Zhao, Simon Garinet, Katia Hormigos, Delphine Le Corre, Jérôme Cros, Karla Perez Toralla, Anne Sophie Bats, Jérémy Augustin, Jean-Baptiste Bachet, Valérie Taly, Hélène Blons, Julien Taieb, Pierre Laurent-Puig
Publikováno v:
Clinics and Research in Hepatology and Gastroenterology
Clinics and Research in Hepatology and Gastroenterology, 2022, 46 (5), pp.101880. ⟨10.1016/j.clinre.2022.101880⟩
Clinics and Research in Hepatology and Gastroenterology, 2022, 46 (5), pp.101880. ⟨10.1016/j.clinre.2022.101880⟩
International audience; Background: Homozygous Recombination Deficiency (HRD) is associated with sensitivity to PARP-inhibitors (PARPi) in different cancer types. In pancreatic adenocarcinoma (PA) the main cause of HRD is BRCA1/2 germline mutation an
Autor:
Pierre Laurent-Puig, Debora Basile, Aziz Zaanan, Raëf Abdallah, Jean-Baptiste Bachet, Daniel Pietrasz, Valérie Taly, Julien Taieb, Shulin Zhao, Léo Mas
Publikováno v:
Cancer Treatment Reviews
Cancer Treatment Reviews, 2020, 87, pp.102028. ⟨10.1016/j.ctrv.2020.102028⟩
Cancer Treatment Reviews, WB Saunders, 2020, 87, pp.102028. ⟨10.1016/j.ctrv.2020.102028⟩
Cancer Treatment Reviews, 2020, 87, pp.102028. ⟨10.1016/j.ctrv.2020.102028⟩
Cancer Treatment Reviews, WB Saunders, 2020, 87, pp.102028. ⟨10.1016/j.ctrv.2020.102028⟩
International audience; While no biomarker is currently recommended for the management of pancreatic adenocarcinoma (PA), circulating tumor DNA (ctDNA) seems promising but little is known on how it may help to manage our patients in the near future.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::034a3bc31f87a4a366b2cb2b1d13f5a8
https://www.hal.inserm.fr/inserm-02992947
https://www.hal.inserm.fr/inserm-02992947
Autor:
Raëf Abdallah, Julien Taieb
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 2 (2019)
ESMO Open
ESMO Open
Pancreatic adenocarcinoma (PA) represents 90% of solid pancreatic malignant tumours. With one of the worst prognoses in oncology (all stages 5-year overall survival (OS) of 9%), PA was the seventh-leading cause of cancer-related deaths worldwide in 2